Abstract
BackgroundImmune checkpoint inhibitors have improved clinical responses and overall survival for patients with non-small cell lung cancer (NSCLC). However, the response is not equal and known NSCLC biomarkers are not...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have